AACR 2024 preview – clinical highlights and lowlights
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Pfizer isn’t done with CD47
Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.
Sensei keeps its eye on VISTA
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.
Astra takes Steap2 into human trials
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
Warning signs for Xencor
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
